← All trials
NCT03983954
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2019
- Primary completion
- Nov 1, 2021
- Completion date
- Feb 28, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 45
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NeoTX Therapeutics Ltd.Lead sponsor
- NeoTX Therapeutics Ltd.Study director
- AstraZenecaCollaborator
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Mesothelioma
- Mutation
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Triple Negative Breast Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.